

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Maslowski John Michael</u>  (Last) (First) (Middle) FIBROCELL SCIENCE, INC. 405 EAGLEVIEW BOULEVARD  (Street) EXTON PA 19341  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Fibrocell Science, Inc. [ FCSC ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <p style="text-align: center;">CEO</p>
	3. Date of Earliest Transaction (Month/Day/Year) 12/13/2019	
6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	12/13/2019		D		3,164	D	\$3 <sup>(1)</sup>	0	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Option to Purchase Common Stock	\$232.5	12/13/2019		D			908	(2)	01/14/2021	Common Stock	908	(2)	0	D	
Option to Purchase Common Stock	\$82.35	12/13/2019		D			1,167	(2)	07/19/2023	Common Stock	1,167	(2)	0	D	
Option to Purchase Common Stock	\$74.25	12/13/2019		D			1,334	(2)	01/17/2024	Common Stock	1,334	(2)	0	D	
Option to Purchase Common Stock	\$44.1	12/13/2019		D			1,334	(2)	05/13/2024	Common Stock	1,334	(2)	0	D	
Option to Purchase Common Stock	\$52.95	12/13/2019		D			6,668	(2)	01/20/2025	Common Stock	6,668	(2)	0	D	
Option to Purchase Common Stock	\$34.05	12/13/2019		D			6,667	(2)	03/01/2026	Common Stock	6,667	(2)	0	D	
Option to Purchase Common Stock	\$9.94	12/13/2019		D			16,667	(2)	12/16/2026	Common Stock	16,667	(2)	0	D	
Option to Purchase Common Stock	\$3.45	12/13/2019		D			20,000	(2)	01/25/2028	Common Stock	20,000	(2)	0	D	
Option to Purchase Common Stock	\$1.78	12/13/2019		D			100,000	(2)	04/12/2029	Common Stock	100,000	(2)	0	D	

Explanation of Responses:

- Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the "Merger Agreement"), among Fibrocell Science, Inc. (the "Company"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of \$3.00.
- Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of \$3.00 over the per share exercise price.

Remarks:

/s/ John M. Maslowski

12/13/2019

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**